MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
41.97
+0.18
+0.43%
After Hours: 41.79 -0.18 -0.43% 19:05 03/28 EDT
OPEN
41.68
PREV CLOSE
41.79
HIGH
42.30
LOW
41.21
VOLUME
579.71K
TURNOVER
0
52 WEEK HIGH
53.18
52 WEEK LOW
22.11
MARKET CAP
2.76B
P/E (TTM)
-14.3777
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CLDX last week (0318-0322)?
Weekly Report · 3d ago
Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald
Dow Jones · 6d ago
Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Benzinga · 6d ago
Weekly Report: what happened at CLDX last week (0311-0315)?
Weekly Report · 03/18 11:15
Market-Moving News for March 15th
Madrigal Pharmaceuticals shares are trading higher after FDA approval of Rezdiffra. Cardlytics shares are higher after the company reported better-than-expected Q4 revenue. Adobe shares are lower after reporting weak guidance and poor financial results. The company's stock is down 12% in the past week.
Benzinga · 03/15 12:36
Weekly Report: what happened at CLDX last week (0304-0308)?
Weekly Report · 03/11 11:12
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Barchart · 03/08 06:00
Notable Wednesday Option Activity: CLDX, GOOG, PSFE
NASDAQ · 03/06 20:37
More
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Webull offers Celldex Therapeutics, Inc. stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.